510(k) device
TULSA-PRO System
Profound Medical, Inc. · High Intensity Ultrasound System For Prostate Tissue Ablation (PLP, Class II) · First FDA decision Aug 15, 2019, newest Sep 20, 2023Prostate cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
510(k) pathway
Device trials
8
Naming "TULSA-PRO"
MAUDE reports
2
Brand "TULSA-PRO", since 2015
PubMed studies
7
Mentioning "TULSA-PRO"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TULSA-PRO System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- TULSA-PRO System510(k)
K230692 · Decided Sep 20, 2023 · 191 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Laser Ablation of the ProstateLocal determinationIn effectL34090CGS Administrators, LLCUpdated Mar 25, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38705Noridian Healthcare Solutions, LLCUpdated Feb 23, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38549Palmetto GBAUpdated Oct 24, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38682WPS Insurance CorporationUpdated Oct 21, 2025
- Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorProposed local determinationProposedDL37421National Government Services, Inc.Updated Sep 18, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38726First Coast Service Options, Inc.Updated Mar 14, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38712Novitas Solutions, Inc.Updated Mar 14, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "TULSA-PRO", any status and sponsor, newest update first.
- Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate CancerSuspended
National Cancer Institute (NCI)NIH
NCT04808427 · 21 participants (planned) · Start Nov 20, 2023 · Primary completion May 1, 2027
Device: TULSA-PRO · For: Prostate Cancer
Sites: Bethesda, Maryland
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TULSA-PRO", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code PLP
33 reports: 1 malfunction, 31 injury, 1 death
Newest reports for this brand
- TULSA-PRO® SYSTEMInjury
3012604011-2024-00001 · Received May 31, 2024 · Event dated Apr 30, 2024
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available; Pelvic Pain
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TULSA-PRO"[tiab]. The summary above synthesizes these.
- Removal of Prostate Calcifications Prior to TULSA-PRO With the Aid of Real-Time Ultrasound Imaging: Our Technique and Experience.
Johnson K, Mehan R · Cureus · 2025
- Improving necrosis estimation in MR-guided prostate focused ultrasound ablations with a probabilistic thermal dose model.
Schröer S, Glandorf J, Düx D, et al. · Comput Biol Med · 2025
- A narrative clinical trials review in the realm of focal therapy for localized prostate cancer.
Lazarovich A, Viswanath V, Dahmen AS, et al. · Transl Cancer Res · 2024Review
- Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial.
Tricard T, Cazzato RL, Schroeder A, et al. · J Vasc Interv Radiol · 2025Clinical Trial
- Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: A GRADE-Assessed Systematic Review and Meta-Analysis.
Nadeem A, Javed D, Iqbal T, et al. · Cardiovasc Intervent Radiol · 2026
- MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 T.
Meyer L, Bohlscheid A, Lemmer O, et al. · Urol Int · 2023
- Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup.
Burtnyk M, Hill T, Cadieux-Pitre H, et al. · J Urol · 2015Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code PLP.
- Focal One®Edap Technomed, Inc. · 510(k) 2025
- Exablate Model 2100V1Insightec, Ltd. · 510(k) 2023
- Tulsa Pro System (Pad-105)Profound Medical, Inc. · 510(k) 2024
- Ablatherm FusionEdap Technomed, Inc. · 510(k) 2017
- SonablateSonacare Medical, LLC · 510(k) 2016
- Ablatherm Integrated ImagingEdap Technomed, Inc. · 510(k) 2015
- Sonablate 450Sonacare Medical, LLC · De Novo 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.